Furthermore, a recent meta-analysis on the effects of SGLT2 inhibitors on cardiovascular events, death, and safety outcomes in adults with T2DM has suggested net protection of SGLT2 inhibitors against cardiovascular outcomes and death [38]. Here, SLC5A2 is linked to type 2 diabetes mellitus.